期刊文献+

基于数据挖掘的中医药防治新型冠状病毒感染中成药用药规律分析 被引量:1

Analysis on Medicine Regularity of Chinese Patent Medicine in Traditional Chinese Medicine for the Prevention and Treatment of COVID-19 Based on Data Mining
下载PDF
导出
摘要 目的:整理分析各省、自治区、直辖市中医药防治新型冠状病毒感染(简称新冠病毒感染)方案,为中成药合理用药提供参考。方法:收集2023年1月10日(含)之前国家及各省、自治区和直辖市卫生健康委员会(卫健委)、中医药管理局(中管局)最新发布的新冠病毒感染防治方案。利用古今医案云平台(V2.3.5)对中成药用药、中医证候、临床症状、中成药功效等进行统计和关联分析。结果:本研究共纳入国家及各省、自治区、直辖市卫健委及中管局发布的新冠病毒感染中医药防治方案31份。方案中面向成年人推荐中成药306种,金花清感颗粒推荐频次最多。面向儿童推荐中成药109种,金振口服液推荐次数最多。连花清瘟胶囊(颗粒)在轻型和中型感染者中推荐频次最高,痰热清注射液和血必净注射液在重型和危重型感染者中推荐次数最多。金花清感颗粒、连花清瘟胶囊(颗粒)、化湿败毒颗粒在成年人发热、咳嗽、咽痛三大临床症状中均作为推荐用药。功效与中成药关联分析提示不同功效的常见药物。结论:中成药在防治新冠病毒感染中具有重要作用,应根据患者临床症状,辨别不同证候合理选用中成药。 Objective:To systematically analyze Chinese medicine prescription protocols for the prevention and treatment of COVID-19and provide references for rational drug use of Chinese patent medicine.Methods:We collected the latest prevention and treatment protocols for COVID-19 by the National Health Commission and the Chinese Medicine Administration(CMA)of each province,autonomous region and municipality directly under the Central Governments before January 10,2023.The Ancient and Modern Medical Records Cloud Platform was used to analyze the Chinese patent medicine,and TCM syndrome.Results:Thirty-one prevention and treatment protocols were reviewed,including 2 national scheme and 28 regional ones.Therewere306 kinds of Chinese patent medicine wererecommended for adults and 109 kinds for children.Lianhua Qingwen capsules(granules)were the highest recommended frequency among early and middle stage.Tanreqing Injection and Xuebijing injection have the highest recommended frequency among severe and critical stage.Jinhua Qing granules,Lianhua Qingwen capsule(granules)and Huashibaidu granules were recommended drugs in the three clinical manifestations of fever,cough and sore throat in adults.Conclusion:Chinese patent medicine plays an important role in the prevention and treatment of COVID-19.Patients should identify different TCM syndromes according to clinical symptoms,and reasonably choose the Chinese patent medicine with different efficacy.
作者 郝佳欣 孙鑫 吴晓丹 孟闫燕 费宇彤 荣红国 HAO Jia-xin;SUN Xin;WU Xiao-dan;MENG Yan-yan;FEI Yu-tong;RONG Hong-guo(School of Traditional Chinese Medicine,Beijing University of Chinese Medicine,Beijing 100029,China;Beijing Institute of Traditional Chinese Medicine,Beijing University of Chinese Medicine,Beijing 100029,China;Institute for Excellence in Evidence-Based Chinese Medicine,Beijing University of Chinese Medicine,Beijing 100029,China;Center for Evidence-Based Chinese Medicine,Beijing University of Chinese Medicine,Beijing 100029,China;National Institute of Chinese Medicine Development and Strategy,Beijing University of Chinese Medicine,Beijing 100029,China)
出处 《中国药物评价》 2023年第2期101-106,共6页 Chinese Journal of Drug Evaluation
基金 北京中医药大学2022年度基本科研业务费(2022-JYB-PY-013) 北京中医药大学2021年度教育科学研究课题(XJY21013)。
关键词 新型冠状病毒感染 数据挖掘 中成药 用药规律 COVID-19 Data mining Chinese patent medicine Medication patterns
  • 相关文献

参考文献13

二级参考文献147

共引文献549

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部